Home Clinical Topics FDA approves hepatitis C drugs for pediatric patients

FDA approves hepatitis C drugs for pediatric patients

On April 7, the U.S. Food and Drug Administration (FDA) approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here